Evidence map›Paper›PMID 26762525›Full record

Trial reportCirculation2016

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.

Michelle L O'Donoghue, Deepak L Bhatt, Gregg W Stone, Ph Gabriel Steg, C Michael Gibson, Christian W Hamm, Matthew J Price, Jayne Prats, Tiepu Liu, Efthymios N Deliargyris and 4 more

Registry-linked trialOpen access · hybridAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01156571 (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01156571 phase3completednot on this map

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)

TypeinterventionalSponsorThe Medicines CompanyRan2010 to 2012Enrolled11,145ConditionsAtherosclerosis, Percutaneous Coronary Intervention, Acute Coronary SyndromeArmscangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Italian Association of Hospital Cardiologists Position Paper 'Gender discrepancy: time to implement gender-based clinical management'.European heart journal supplements : journal of the European Society of Cardiology · 2024
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Michelle L O'DonoghueFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.). modonoghue@partners.org.
Deepak L BhattFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Gregg W StoneFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Ph Gabriel StegFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
C Michael GibsonFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Christian W HammFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Matthew J PriceFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Jayne PratsFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Tiepu LiuFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Efthymios N DeliargyrisFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Kenneth W MahaffeyFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Harvey D WhiteFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Robert A HarringtonFrom Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.L.O., D.L.B.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY (G.W.S.); FACT, DHU FIRE, Université Paris-Diderot, Sorbonne Paris-Cité, France (G.S.); LVTS INSERM U-1148, Hôpital Bichat, HUPNVS, AP-HP, Paris, France (G.S.); NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (G.S.); Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.); The Medicines Company, Parsippany, NJ (J.P., T.L., E.N.D.); Stanford University Medical School, Stanford, CA (K.W.M., R.A.H.); and Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
CHAMPION PHOENIX Investigators
Inserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCangrelor is an intravenous ADP receptor antagonist that leads to potent and reversible inhibition of platelet aggregation. The relative safety and efficacy of some antiplatelet drugs in women has been disputed. METHODS AND

resultsThe Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial randomized 11,145 patients undergoing elective or urgent percutaneous coronary intervention to cangrelor or clopidogrel. The primary efficacy end point was the composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours; the key secondary end point was stent thrombosis at 48 hours. The primary safety end point was GUSTO severe bleeding at 48 hours. Of subjects analyzed, 3051 (28%) were female. Cangrelor reduced the odds of the primary end point by 35% in women (adjusted odds ratio [OR], 0.65; 95% confidence interval [CI], 0.48-0.89) and by 14% in men (OR, 0.86; 95% CI, 0.70-1.05; P interaction=0.23) compared with clopidogrel. Cangrelor reduced the odds of stent thrombosis by 61% in women (OR, 0.39; 95% CI, 0.20-0.77) and 16% in men (OR, 0.84; 95% CI, 0.53-1.33; P interaction=0.11). The odds of severe bleeding were similar in both women and men treated with cangrelor (0.3% versus 0.2%, P=0.30 [women]; 0.1% versus 0.1%, P=0.41 [men]; P interaction=0.88) versus clopidogrel. Cangrelor increased the odds of moderate bleeding in women (0.9% versus 0.3%, P=0.02), but not in men (0.2% versus 0.2%, P=0.68; P interaction=0.040). The net clinical benefit (primary efficacy and safety end point) favored cangrelor in both women (OR, 0.68; 95% CI, 0.50-0.92) and men (OR, 0.87; 95% CI, 0.71-1.06; P interaction=0.26).

conclusionsIn CHAMPION PHOENIX, cangrelor reduced the odds of major adverse cardiovascular events and stent thrombosis in women and men and appeared to offer greater net clinical benefit than clopidogrel. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT01156571.

Indexed as

Disease ManagementSex CharacteristicsAdenosine MonophosphateAgedAged, 80 and overFemaleHemorrhageHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsTreatment OutcomeAdenosine MonophosphatecangrelorPlatelet Aggregation InhibitorsADP receptor antagonistcangrelorclopidogrelpercutaneous coronary intervention

Identifiers

PMID26762525
PMCPMC4894784
OpenAlexW2287929000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.